09:54 AM EST - Valeant Pharmaceuticals International, Inc. : announced today that it has acquired Visudyne®, used to treat abnormal growth of leaky blood vessels in the eye caused by wet age-related macular degeneration, from QLT Inc. Valeant paid $62.5 million upfront for all U.S. rights and available inventories for Visudyne, which had U.S. revenue of approximately $21 million in 2011, and another $50 million upfront for rights to non-U.S. royalties on Visudyne sales, which were approximately $14 million in 2011. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading up $0.20 at $53.55.
